Get started
Author

Hirotaka Matsumoto

Observed names: H. Matsumoto, HIROTAKA MATSUMOTO, Matsumoto, Hirotaka
ORCID: 0000-0003-4538-6456
Observed ORCID: 0000-0003-4538-6456
OpenAlex ID: A5047323268
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
2021 · Yoshihiko Sakata, Shinya Sakata, et al. · European Journal of Cancer · 101
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)
2021 · Go Saito, Yuko Oya, et al. · Lung Cancer · 63
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
2023 · Yoshimasa Shiraishi, Junji Kishimoto, et al. · JAMA Oncology · 58
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
2021 · Daichi Fujimoto, Satoru Miura, et al. · JTO Clinical and Research Reports · 55
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
2019 · Hayato Kawachi, Motohiro Tamiya, et al. · Investigational New Drugs · 53
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
2019 · Motohiro Tamiya, Akihiro Tamiya, et al. · Investigational New Drugs · 52
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer
2022 · Yuki Sato, Hiromitsu Sumikawa, et al. · CHEST Journal · 51
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
2020 · Kazutaka Hosoya, Daichi Fujimoto, et al. · Clinical Lung Cancer · 44
Histologic transformation of epidermal growth factor receptor–mutated lung cancer
2022 · Daichi Fujimoto, Hiroaki Akamatsu, et al. · European Journal of Cancer · 36
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
2021 · Kazutaka Hosoya, Daichi Fujimoto, et al. · BMC Cancer · 34
PDF
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
2023 · Daichi Fujimoto, Takeshi Morimoto, et al. · JAMA Network Open · 32
PDF
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC
2025 · Kentaro Tanaka, Jun Sugisaka, et al. · Nature Communications · 28
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)
2024 · Kageaki Watanabe, Yukio Hosomi, et al. · JTO Clinical and Research Reports · 25
PDF
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
2024 · Ryota Shibaki, Daichi Fujimoto, et al. · Journal for ImmunoTherapy of Cancer · 24
PDF
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study
2022 · Mihoko Imaji, Daichi Fujimoto, et al. · European Journal of Cancer · 24
Influence of social isolation and loneliness on the prognosis of advanced lung cancer patients: a prospective cohort study
2022 · Tomoyasu Takemura, Yuki Kataoka, et al. · Supportive Care in Cancer · 19
PDF
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center
2017 · Takehiro Otoshi, Yuki Kataoka, et al. · PLoS ONE · 18
PDF
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)
2023 · Yoshihiko Sakata, Go Saito, et al. · Lung Cancer · 16
First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan
2022 · Yasushi Goto, Atsuhisa Tamura, et al. · JTO Clinical and Research Reports · 14
PDF
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis
2022 · Takeya Sugimoto, Daichi Fujimoto, et al. · Lung Cancer · 14
Influence of social determinants of health on patients with advanced lung cancer: a prospective cohort study
2018 · Tomoyasu Takemura, Yuki Kataoka, et al. · BMJ Open · 14
PDF
Factors Influencing Social Isolation and Loneliness Among Lung Cancer Patients: A Cross-sectional Study
2020 · NANAMI ASHI, YUKI KATAOKA, et al. · Anticancer Research · 12
PDF
Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study
2023 · Yuki Sato, Satoru Fujiwara, et al. · JTO Clinical and Research Reports · 10
PDF
Real-world survey of pneumonitis/radiation pneumonitis among patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy after durvalumab approval: A multicenter retrospective cohort study (HOPE-005/CRIMSON).
2020 · Go Saito, Yuko Oya, et al. · Journal of Clinical Oncology · 10
Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review
2019 · Takuma Imakita, Hirotaka Matsumoto, et al. · BMC Cancer · 9
Works count: 78
Citation count: 897
H-index: 17
I10-index: 24
Year
Topic
Type